ST Germain D J Co. Inc. Buys 4,515 Shares of Pfizer Inc. (NYSE:PFE)

ST Germain D J Co. Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 17.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 30,269 shares of the biopharmaceutical company’s stock after buying an additional 4,515 shares during the period. ST Germain D J Co. Inc.’s holdings in Pfizer were worth $803,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. ORG Partners LLC lifted its stake in shares of Pfizer by 6.2% in the fourth quarter. ORG Partners LLC now owns 50,879 shares of the biopharmaceutical company’s stock valued at $1,351,000 after buying an additional 2,967 shares during the period. First International Bank & Trust bought a new stake in shares of Pfizer in the fourth quarter valued at about $240,000. Legacy Private Trust Co. lifted its stake in shares of Pfizer by 29.0% in the fourth quarter. Legacy Private Trust Co. now owns 13,766 shares of the biopharmaceutical company’s stock valued at $365,000 after buying an additional 3,093 shares during the period. InvesTrust bought a new stake in shares of Pfizer in the fourth quarter valued at about $5,246,000. Finally, Sterneck Capital Management LLC lifted its stake in shares of Pfizer by 76.2% in the fourth quarter. Sterneck Capital Management LLC now owns 32,630 shares of the biopharmaceutical company’s stock valued at $866,000 after buying an additional 14,107 shares during the period. Institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Wolfe Research assumed coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Finally, Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.73 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market cap of $151.48 billion, a P/E ratio of 36.12, a P/E/G ratio of 0.63 and a beta of 0.64. The firm has a 50 day simple moving average of $26.18 and a 200 day simple moving average of $28.04. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.17) earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.43%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 232.43%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.